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Abstract
The authors sought to assess whether viral load (VL) monitoring frequency was associated with 
differential rates of virologic failure (VF) among HIV Outpatient Study (HOPS) participants seen 
during 1999 to 2013, who had maintained VL <50 copies/mL, CD4 counts ≥300 cells/mm3, and 
been prescribed a stable combination antiretroviral regimen for at least 2 years. The authors 
required VL and CD4 testing to have occurred regularly for the entire 2-year period. The authors 
assessed rates of VF comparing patients who maintained a frequent VL testing (≥3 VLs) to those 
who shifted to a less frequent schedule (2 VL) after the 2-year period. Virologic failure was 
observed among 116 of 573 participants. The authors did not detect statistically significant 
difference in frequency of VF among patients undergoing frequent (21.0%) versus less frequent 
VL testing (19.6%), even after multivariable adjustment. Biannual VL monitoring for stable 
patients with aviremia could generate substantial cost savings without the increased risk of VF.
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Background
HIV-infected persons who have access to medical care and are prescribed combination 
antiretroviral therapy (cART) are increasingly living longer and experience lower rates of 
treatment failure.1,2 Intuitively, it is reasonable that the requirement for laboratory 
monitoring of stable patients might be less frequent, yet there are sparse data to support this 
notion. Monitoring plasma HIV RNA levels (viral load [VL]) is recommended as part of 
routine care for HIV-infected persons, and achieving and maintaining VL suppression are 
considered critical indicators of successful response to cART.3 Current US Department of 
Health and Human Services (DHHS) treatment guidelines recommend obtaining routine VL 
testing every 3 to 4 months, except for patients who have had undetectable VLs while on 
cART for more than 2 to 3 years and who are stable clinically and immunologically; for 
such patients, VL testing frequency may be decreased to every 6 months.3 This DHHS 
recommendation received an AIII rating, meaning that it was of strong strength but was 
based only on expert opinion. Because the financial cost of laboratory diagnostics represents 
a substantial portion of total health care costs for HIV-infected persons, biannual VL 
frequency could result in significant reductions in financial costs of laboratory diagnostics, 
provided that such monitoring strategy is proven to be sufficient and safe (ie, not associated 
with adverse events). Recognizing the DHHS Panel’s recommendation, the lack of scientific 
literature on this subject, and the recently expanded World Health Organization 
recommendation for reduced frequency of VL monitoring to every 6 months in low- and 
middle-income countries,4 we investigated the clinical consequences of performing biannual 
VL testing among clinically and immunologically stable cART-treated patients followed in a 
large observational HIV cohort study in the United States.
Methods
The HIV Outpatient Study Cohort
The HIV Outpatient Study (HOPS) cohort is an ongoing, open, prospective cohort study 
since 1993 that has followed over 10 000 HIV-infected adults (aged 18 years and older) 
receiving HIV outpatient care.5 Participating clinics provide care to a total of approximately 
3000 HOPS participants each year. The 11 clinics included in the present analyses were 
located in 8 US cities: Tampa, Florida; Washington, District of Columbia; Denver, Colorado 
(3 sites); Oakland, California; San Leandro, California; Chicago, Illinois (2 sites); 
Stonybrook, New York; and Philadelphia, Pennsylvania. The HOPS protocol has been 
approved and renewed annually by the Centers for Disease Control and Prevention (CDC) 
and each participating institution’s ethical review board. All study participants have 
provided written informed consent. All HOPS clinicians have extensive experience treating 
HIV-infected patients. Information was abstracted from outpatient charts at each visit, 
entered electronically by trained staff, compiled centrally, and reviewed and edited before 
being analyzed. Abstracted information includes demographic characteristics, risk factors 
for HIV infection, diagnoses, prescribed medications, laboratory values (including CD4 
counts and VLs), mortality, and hospitalization records (primarily from discharge 
summaries).
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Study Population
We included in the analyses patients enrolled in HOPS who had suppressed plasma HIV 
VLs (VL < 50 copies/mL) for at least 2 years and were prescribed a stable, nonsalvage 
cART regimen outside a research clinical trial for the same 2-year period. Regimens 
containing enfuvirtide or maraviroc were considered to be salvage regimens, and patients 
prescribed these regimens were excluded from the analyses. Eligible participants could be 
prescribed either their first or subsequent cART regimen, but the regimen must have been 
consistent throughout the 2-year period of viral suppression. Dose changes switches from 
component drugs to combination drugs and changes from emtricitabine to lamivudine (3TC) 
or vice versa were not considered changes to the regimen, but all other changes were not 
permitted and caused patients to be excluded from the analyses. Patients were further 
required to have regular VL and CD4 testing performed during this 2-year period: At least 3 
VLs and 3 CD4 tests were required in each year with the first and the last being at least 6 
months apart (see Figure 1). Finally, consistent with the latest DHHS guidelines on 
immunological stability and VL testing,3 all CD4 tests in the 2-year period must have had a 
result of at least 300 cells/mm3. The “index date,” the start of observation for this analysis, 
was defined as the date of the last VL obtained during the 2-year lead-in period as shown in 
Figure 1. Finally, in the year immediately following the index date, we required patients to 
have had at least 2 VL tests completed so that the predictor (exposure) variable of interest, 
namely, the frequency of VL testing, could be established.
Outcome and Independent Variable Definitions
The key predictor variable of interest was the frequency of VL testing performed in the year 
immediately following the index date. Patients who met the criteria (at least 3 VLs 
performed in the year at least 6 months between first and last) qualified as frequent testers, 
and those who had 2 VLs performed during the year were classified as less frequent testers 
(patients with only 1 VL were omitted from further analyses). The outcome of interest was 
time to virologic failure (VF), which we defined as at least 1 VL ≥ 200 copies/mL during the 
2-year followup period after the index date (please see Figure 1). Observation terminated at 
the earliest among the following dates: date of VF, death, loss to follow-up, change in cART 
regimen, the end of 2 years of observation, or December 31, 2013.
Race/ethnicity was grouped into non-Hispanic/Latino white, non-Hispanic/Latino black or 
African American (hereinafter referred to as non-Hispanic/Latino black), Hispanic/Latino, 
and other/unknown. Participants’ HIV transmission risk was categorized based on self-
reported behavior at HOPS enrollment. When multiple risk behaviors were reported, we 
classified risk hierarchically as follows: persons who inject drugs (IDUs); followed by gay, 
bisexual, and other men who have sex with men (collectively referred to as MSM), 
heterosexuals; and persons in other/unknown category. Health insurance status was defined 
based on self-reported type of health care payor closest to the index date. We defined nadir 
CD4 as the lowest value reported prior to the index date, and baseline VL and CD4 were the 
values closest to the index date during the preceding 6 months. Regimens were considered 
cART when meeting standard criteria as described previously.6 We categorized regimens as 
≥3 nucleoside reverse transcriptase inhibitors (NRTIs); integrase inhibitor (INT) and NRTIs; 
nonnucleoside reverse transcriptase inhibitor (NNRTI) and NRTIs; and protease inhibitor 
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(PI), NNRTI, and NRTIs; and PI and NRTIs. Tobacco smoking status was based on self-
report at HOPS enrollment. One of the following was used to indicate coinfection with 
hepatitis C prior to the index date: a diagnosis of hepatitis C, a positive hepatitis C antibody 
test, a positive hepatitis C viral load, or a positive hepatitis C genotype test
Statistical Analyses
We analyzed observations through December 31, 2013, using data available as of June 30, 
2014, to account for any delays in data abstraction and entry. Chi-square tests and 2-sided 
Wilcoxon tests were used to compare baseline characteristics of frequent VL testers and less 
frequent VL testers. We performed Kaplan-Meier time-to-event analyses as well as 
univariate Cox proportional hazard regressions to determine the association between VF 
during the 2-year follow-up period and the following baseline (at index date) characteristics: 
age, sex, race/ethnicity, HIV risk category, insurance, CD4, hepatitis C coinfection, and 
frequency of VL testing in the year immediately following the index date. All characteristics 
in univariate analyses were included in the multivariable model to adjust for potential 
confounding. All analyses were performed in SAS 9.3.
Results
We identified 3156 HOPS participants with at least 2 years of viral suppression, of whom 
2168 remained on a single cART regimen during that 2-year period and 972 maintained 
consistent VL testing (defined as at least 3 VLs per year at least 6 months apart). We 
excluded from the analyses 61 patients whose CD4 fell below 300 cells/mm3 during that 2-
year period, and a further 69 patients who did not maintain regular CD4 monitoring (defined 
as at least 3 CD4 tests per year at least 6 months apart), thus resulting in 842 participants. Of 
those, 573 had sufficient data to be classified as either frequent VL testers or less frequent 
VL testers in the year immediately following the 2-year period of viral suppression.
The 573 participants included in this analysis had the following characteristics at the index 
date: median (interquartile range [IQR]) age 46.1 years (IQR 39.9–53.5), 80.6% male, 
62.5% non-Hispanic/Latino white, 66.1% MSM, and median CD4 599 cells/mm3 (IQR 442–
809). We classified the main exposure variable for the 573 participants in the analysis as 
follows: 252 (44.0%) had frequent VL testing performed in the year after the index date, 
while 321 (56.0%) had less frequent testing performed (Table 1). Those with frequent 
testing and less frequent testing did not differ significantly by age, sex at birth, race/
ethnicity, HIV risk category, AIDS status, nadir or baseline CD4, cART classification, 
history of smoking, or hepatitis C coinfection. There was a numerical difference in the 
frequency of private insurance coverage between the 2 groups, although this difference did 
not reach statistical significance (P = .06). Over the study period, the percentage of patients 
who underwent ≤2 VL tests during the year following the index date increased (Figure 2), 
reaching 66% among individuals whose index date was 2011 to 2013. The mean number of 
VL tests per patient, however, remained similar: 4.6 tests/year in 1999 to 2000 versus 4.5 in 
2011 to 2013.
There were 116 (20.2%) participants who experienced VF during the 2-year follow-up 
period: 53 (21.0%) persons with frequent VL testing compared to 63 (19.6%) persons less 
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frequent VL testing (chi-square P value .71). Frequency of virologic testing during the year 
after index date was not associated with subsequent VF in univariate (hazard ratio [HR] 1.1, 
95% confidence interval [CI] 0.8–1.7) or multivariable Cox proportional hazards regression 
models (adjusted HR: 1.2, 95% CI: 0.8–1.7; Table 2). Other factors were similarly not 
associated with time to VF, including age, sex, race/ethnicity, HIV risk category, insurance, 
baseline CD4, or hepatitis C coinfection in either univariate or multivariable models.
Conclusion
In this large convenience sample of immunologically stable and virologically suppressed US 
HIV-infected persons prescribed cART, less frequent VL testing became more common 
over time. Having 2 VL tests per year was not associated with an increased rate of VF as 
compared with having at least 3 viral load tests per year at least 6 months apart. These data 
are similar to data reported by Romih and colleagues in Croatia involving a smaller cohort 
of 128 patients initiating cART, in which there was no difference in VL monitoring 
frequency between patients who did or did not experience VF.7 Another small randomized 
prospective study found no difference in VF rates among 165 individuals with CD4 ≥250 
cells/mm3 and undetectable VLs for more than 12 months who were randomized to receive 
VL monitoring either every 4 or every 6 months.8
According to the US Center for Medicare and Medicaid Services, in 2014, the average VL 
test cost was US$116.9. We estimate that reducing testing frequency from 3 to 4 VLs per 
year to 2 times per year may save between US$116 and US$232 per patient-year. This value 
does not include the human resource costs in provider counseling time for each test or the 
costs associated with any morbidity associated with unnecessary phlebotomy.
Studies that examined the effects of reducing CD4 count measurements in persons with CD4 
counts stably ≥350 cells/mm3 while virologically suppressed have demonstrated that 
reduced testing is safe (ie, few patients experience clinically meaningful immunologic 
declines that could be missed) and could result in large cost savings that could be applied to 
improve and expand clinical care for HIV-infected persons.10 Savings resulting from 
decreasing the frequency of CD4 monitoring could be used in other ways to improve clinical 
outcomes for HIV-infected persons.11 Similarly, decreasing the frequency of VL monitoring 
among clinically stable and effectively treated patients could result in cost savings that could 
be reinvested in improving other aspects of patient care.
Strengths of this analysis include its large sample size and duration of follow-up. Our 
findings are also subject to important limitations, including our inability to examine 
mortality as that outcome was too rare in our cohort. Although the patients included in our 
analysis were, in general, demographically well balanced between the 2 groups we 
compared, there may have been unaccounted for channeling bias (eg, patients perceived to 
have been more adherent had VL tested less frequently). We also could not assess the extent 
to which less frequent VL monitoring was an intentional choice on the part of clinicians or 
may have resulted from patients missing their clinical appointments or patient preference. 
To this point, we note that patients with private insurance tended to have less frequent viral 
load testing. It is possible that the lack of difference in VF rates could reflect 2 contrasting 
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clinical scenarios. In one, there are more privately insured patients among the less frequent 
testers, and private insurance might be a surrogate marker for greater affluence and/or fewer 
comorbidities. Hence, less frequent VL testing might result from patients and clinicians 
recognizing that less frequent VL testing is sufficient in the presence of better clinical status 
or optimal adherence to care and ART. In the second scenario, less frequent VL testing 
could be the result of missed clinic visits, missed laboratory draws, and overall poorer 
adherence to ART and care. Further, our study participants were somewhat older than 
persons in the general US population of HIV-infected adults, and only a small percentage 
(9.1%) were under the age of 35 years, thus limiting our ability to generalize our conclusions 
for younger adult patients and precluding inferences to children and adolescents aged <18 
years whom HOPS does not include. Finally, HOPS is conducted in well-established urban 
HIV specialty clinics, and, therefore, aspects of care, engagement in care, and laboratory 
monitoring may differ from less experienced HIV care environments. Because of these 
caveats, and because our study population was restricted, by design, to patients who 
continuously maintained CD4 ≥300 cells/mm3 during observation, we caution clinicians to 
carefully interpret our findings and allow for individualized VL testing schedules among 
their patients, which can be adjusted over time, as appropriate.
In summary, our findings from this large observational cohort study support current US 
recommendations for biannual VL monitoring among clinically stable and virologically 
suppressed HIV-infected patients.3 In our cohort, VL monitoring at this frequency was not 
associated with increased rates of VF during a 2-year follow-up period. While our 
experience may not be generalizable to all clinical care settings, we believe the biannual VL 
monitoring for the qualifying patients could generate substantial financial cost savings 
without jeopardizing patient safety, freeing the resources to expand, and improve other 
aspects of HIV care, such as supportive and ancillary services, including adherence and 
retention support.
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Figure 1. 
Schematic of analytic design, including definition of HIV viral load (VL) testing, frequency 
(exposure), and virologic failure (outcome). cART indicates combination antiretroviral 
therapy; VL, viral load.
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Figure 2. 
Mean number of viral load tests and the frequency of viral load testing performed in the year 
after index date, the HIV Outpatient Study (N = 573). VL indicates viral load. Embedded in 
the bars are numbers of participants represented.
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Table 2
Association of Frequency of Viral Testing with Time to Virologic Failure,a the HIV Outpatient Study, 1999 to 
2013.b
Univariate Multivariable
Characteristic Hazard Ratio P Value Hazard Ratio P Value
Age at index date,c years
  <35 1.3 (0.7–2.6) .43 1.3 (0.6–2.6) .47
  35–49 1.4 (0.9–2.2) .09 1.5 (0.9–2.2) .09
  ≥50 Referent Referent
Sex at birth
  Female 1.0 (0.6–1.6) .93 1.0 (0.5–1.9) .90
  Male Referent Referent
Race/ethnicity
  Non-Hispanic/Latino white Referent Referent
  Non-Hispanic/Latino black 1.2 (0.8–1.9) .35 1.2 (0.8, 2.0) .40
  Hispanic/Latino 0.8 (0.4–1.5) .52 0.8 (0.4–1.5) .45
  Other/unknown 1.2 (0.5–2.9) .72 0.9 (0.4–2.3) .85
HIV risk transmission category
  Heterosexual 1.0 (0.6–1.6) .94 1.1 (0.5–2.2) .79
  IDU 0.9 (0.5–1.8) .80 1.0 (0.4–2.4) .94
  MSM Referent Referent
  Other/unknown 1.3 (0.6–2.5) .51 1.3 (0.6–2.8) .54
Insurance
  Private Referent Referent
  Public 0.7 (0.5–1.2) .19 0.7 (0.4–1.1) .14
  Self-pay/none 1.5 (0.8–2.8) .20 1.4 (0.7–2.8) .29
  Other/unknown 1.2 (0.4–3.8) .77 1.2 (0.4–4.0) .74
CD4d at index date, cells/mm3
  300–349 0.8 (0.4–1.6) .50 0.9 (0.4–1.8) .70
  350–499 1.2 (0.8–1.8) .46 1.3 (0.9–2.0) .21
  500+ Referent Referent
Hepatitis C coinfection at index date
  Yes 1.0 (0.6–1.5) .89 1.1 (0.6–1.8) .78
  No Referent Referent
VL testinge
  Frequent 1.1 (0.8–1.7) .46 1.2 (0.8–1.7) .36
  Less frequent Referent Referent
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; cART, combination antiretroviral therapy; Enh, enhancers; IDU, injection drug 
user; INT, integrase inhibitors; IQR, interquartile range; MSM, gay, bisexual, and other men who have sex with men; NNRTIs, nonnucleoside 
reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; VL, viral load.
aVirologic failure is the first viral load test ≥200 copies/mL.
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bN = 573.
c
Index date is the end date of the 2-year lead-in period after which primary exposure (VL testing frequency) is defined and occurrence of viral 
failure assessed (see Figure 1).
dClosest value to index from values documented 6 months prior to 3 months post index date.
e
Frequent VL testers: patients who had at least 3 viral load tests in the year after index date with at least 6 months between the first and last test. 
Less frequent VL testers: patients who had 2 viral load laboratory tests in the year after index date.
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